ArticleVirchows Archiv : an international journal of pathology2010
Expression of resistin-like molecule beta in gastric cancer: its relationship with clinicopathological parameters and prognosis.
Article in Virchows Archiv : an international journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Context-dependent roles of resistin-like molecule β in mucosal defense and inflammatory diseases.Frontiers in immunology · 2026Review
- Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases.Cell communication and signaling : CCS · 2023Review
- The Mechanisms of Resistin-Like Molecule-β-Mediated Airway Inflammation in Chronic Obstructive Pulmonary Disease via Autophagy.Journal of inflammation research · 2023Article
- Article
- Investigating resistin like beta (RETNLB) as a tumor promoter for oral squamous cell carcinoma.Head & face medicine · 2021Article
- Helicobacter pylori Infection Facilitates the Expression of Resistin-like Molecule Beta in Gastric Carcinoma and Precursor Lesions.Current medical science · 2020Article
- Increased resistin suggests poor prognosis and promotes development of lung adenocarcinoma.Oncology reports · 2018Article
- Here, there and everywhere: Resistin-like molecules in infection, inflammation, and metabolic disorders.Cytokine · 2018Review
- NF-κB Signaling in Gastric Cancer.Toxins · 2017Review
- Resistin-Like Molecule-β Promotes Invasion and Migration of Gastric Carcinoma Cells.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Human resistin and the RELM of Inflammation in diabesity.Diabetology & metabolic syndrome · 2015Article
- The overexpression of AP-4 as a prognostic indicator for gastric carcinoma.Medical oncology (Northwood, London, England) · 2012Article
- Effects of resistin-like molecule β over-expression on gastric cancer cells in vitro.World journal of gastroenterology · 2012Article
- Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis.Journal of cancer research and clinical oncology · 2012Article
- Plasma levels of resistin-like molecule beta in humans.Cancer epidemiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistin-like molecule beta (RELMbeta), an intestinal goblet cell-specific protein, is a biomarker of intestinal metaplasia in Barrett's esophagus and over-expressed in colon cancer. Since gastric adenocarcinomas can arise through a process of intestinalization, we hypothesized that RELMbeta might be aberrantly expressed in gastric cancer. This study was undertaken to examine the RELMbeta expression in gastric cancer and correlate it with clinical outcome. One hundred and thirty-six gastric cancer patients were evaluated for the RELMbeta expression by immunohistochemistry. The RELMbeta transcripts were measured by real-time quantitative PCR. In normal gastric mucosa, RELMbeta expression was absent, whereas areas of intestinal metaplasia revealed RELMbeta reactivity. Eighty-nine patients of gastric cancer (65.4%) were positive for RELMbeta expression. In a subtotal of 20 patients, RELMbeta transcripts were positively correlated with protein levels in gastric cancer tissues, but absent in normal gastric mucosa. The expression rate of RELMbeta was higher in intestinal-type carcinomas than in diffuse-type carcinomas (P < 0.001). RELMbeta positivity in gastric cancer was positively correlated with tumor differentiation (P = 0.001) and inversely correlated with tumor infiltration (P = 0.007), lymph node metastasis (P = 0.035), and heparanase expression (P < 0.001), without correlation with age, gender, tumor location and size, tumor-node metastasis stages, and Ki-67 expression. Patients showing positive RELMbeta expression had a significantly longer overall survival than those with negative expression (P = 0.001). These results provide evidences that the RELMbeta expression in gastric cancer is correlated with clinicopathological features and may be a useful prognostic factor for predicting the outcome of gastric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.